BCMA, B-cell maturation antigen; CD, cluster of differentiation; MOA, mechanism of action; MOD, mechanism of disease; PARP, poly ADP ribose polymerase; PD-1, programmed cell death protein 1; PVRIG, poliovirus receptor–related immunoglobulin; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TIM-3, T-cell immunoglobulin and mucin domain-3.

*In-license or other partnership with third party.
^†Collaboration and license alliance between GSK and iTeos Therapeutics.

This document contains information for healthcare providers and is intended solely for educational purposes. This display includes ongoing clinical trials for both approved and investigational compounds. Some agents are approved in select indications. Inclusion in this display does not imply regulatory approval for these compounds or all indications. Information about all trials can be found at www.clinicaltrials.gov. All clinical study information updated as of April 10, 2023.